ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer

Zhong, Yue; Peng, Fu; Luo, Xiaoru; Wang, Xuan; Yang, Bowen; Tang, Xinglinzi; Xu, Zheng; Ren, Linlin; Wang, Zhiyu*; Peng, Cheng*; Wang, Neng*广东省人民医院; 广州中医药大学; 四川大学
Frontiers in Oncology2022-12-23DOI: 10.3389/fonc.2022.964508
2被引16阅读
引用收藏
分享

摘要

PurposePyroptosis exerts an undesirable impact on the clinical outcome of breast cancer. Since any single gene is insufficient to be an appropriate marker for pyroptosis, our aim is to develop a pyroptosis-related gene (PRG) signature to predict the survival status and immunological landscape for breast cancer patients. MethodsThe information of breast cancer patients was retrieved from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the gene expressions of this signature in breast cancer. Its prognostic value was evaluated by univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression analysis, receiver operating characteristics (ROCs), univariate/multivariate analysis, and nomogram. Analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed to explore its potential biological function in breast cancer. The potential correlation between this signature and tumor immunity was revealed based on single sample gene set enrichment analysis (ssGSEA), ESTIMATE and CIBERSORT algorithms. ResultsA PRG signature containing GSDMC, GZMB, IL18, and TP63 was created in a TCGA training cohort and validated in two validation GEO cohorts GSE58812 and GSE37751. Compared with a human mammary epithelial cell line MCF-10A, the expression levels of GSDMC, GZMB and IL18 were upregulated, while TP63 was found with lower expression level in breast cancer cells SK-BR-3, BT-549, MCF-7, and MDA-MB-231 using RT-qPCR assay. Based on univariate and multivariate Cox models, ROC curve, nomogram as well as calibration curve, it was revealed that this signature with high-risk score could independently predict poor clinical outcomes in breast cancer. Enrichment analyses demonstrated that the involved mechanism was tightly linked to immune-related processes. SsGSEA, ESTIMATE and CIBERSORT algorithms further pointed out that the established model might exert an impact on immune cell abundance, immune cell types and immune-checkpoint markers. Furthermore, individuals with breast cancer responded differently to these therapeutic agents based on this signature. ConclusionsOur data suggested that this PRG signature with high risk was tightly associated with impaired immune function, possibly resulting in an unfavorable outcome for breast cancer patients.

学科与关键词

关键词
breast cancerpyroptosis4-gene signaturesurvival statusimmunological landscape
相关
加载中…
  • Identification of a pyroptosis-related prognostic signature in breast cancer
    Chen, Hanghang; Luo, Haihua; Wang, Jieyan; Li, Jinming*; Jiang, Yong*BMC CANCER, 2022, 22(1): 429.被引 16
  • A pyroptosis-related gene signature that predicts immune infiltration and prognosis in colon cancer
    Wu, Mingjian; Hao, Shuai; Wang, Xiaoxiang; Su, Shuguang; Du, Siyuan; Zhou, Sitong*; Yang, Ronghua*; Du, Hanpeng*Frontiers in Oncology, 2023, 13: 1173181.
  • Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer
    Zhang, Guian; Luo, Yong; Dong, Weimin; Zhong, Weide*Computational and Mathematical Methods in Medicine, 2022, 2022: 8233840.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-12-23
卷期
第 12 卷
页码
964508
DOI
10.3389/fonc.2022.964508
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973526, 81873306, 82004132]; Guangdong Traditional Chinese Medicine Bureau Project [20211114]; State Key Laboratory of Dampness Syndrome of Chinese Medicine [SZ2021ZZ19]; 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) [2020B1212030006]; Science and Technology Planning Project of Guangdong Province [2017B030314166]; Guangdong Science and Technology Department [2021A0505030059]; Guangzhou Science and Technology Project [202102010316]; Open Research Fund of Chengdu University of Traditional Chinese Medicine State Key Laboratory of Characteristic Chinese Medicine Resources in Southwest China [XZYZ-20201224-1945]; Funding for Young Scholars of Guangzhou University of Chinese Medicine [QNYC20190101]

作者

  • Z

    Zhong, Yue (第一作者)

    guangzhou univ chinese med

  • P

    Peng, Fu

    sichuan univ · chengdu univ tradit chinese med

查看全部 11 位作者收起作者
  • L

    Luo, Xiaoru

    guangzhou univ chinese med

  • W

    Wang, Xuan

    guangdong prov acad chinese med sci · guangdong prov hosp · guangzhou univ chinese med · 2

  • Y

    Yang, Bowen

    guangdong prov acad chinese med sci · guangdong prov hosp · guangzhou univ chinese med · 2

  • T

    Tang, Xinglinzi

    guangzhou univ chinese med

  • X

    Xu, Zheng

    guangzhou univ chinese med

  • R

    Ren, Linlin

    guangzhou univ chinese med

  • W

    Wang, Zhiyu (通讯)

    guangdong prov acad chinese med sci · guangdong prov hosp · guangzhou univ chinese med · 2

  • P

    Peng, Cheng (通讯)

    chengdu univ tradit chinese med

  • W

    Wang, Neng (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417